ClinVar Miner

Submissions for variant NM_001079802.2(FKTN):c.437G>A (p.Arg146Gln)

gnomAD frequency: 0.00005  dbSNP: rs143748939
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000396885 SCV000336065 uncertain significance not provided 2018-08-16 criteria provided, single submitter clinical testing
Invitae RCV000687793 SCV000815380 uncertain significance Walker-Warburg congenital muscular dystrophy 2022-08-23 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 146 of the FKTN protein (p.Arg146Gln). This variant is present in population databases (rs143748939, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with FKTN-related conditions. ClinVar contains an entry for this variant (Variation ID: 283759). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FKTN protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV000396885 SCV001752381 uncertain significance not provided 2021-05-19 criteria provided, single submitter clinical testing In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge
Genetic Services Laboratory, University of Chicago RCV001820816 SCV002071527 uncertain significance not specified 2020-07-17 criteria provided, single submitter clinical testing DNA sequence analysis of the FKTN gene demonstrated a sequence change, c.437G>A, in exon 6 that results in an amino acid change, p.Arg146Gln. This sequence change does not appear to have been previously described in patients with FKTN-related disorders and has been described in the gnomAD database with a low frequency of 0.04% in the Finnish sub-population (dbSNP rs143748939). The p.Arg146Gln change affects a highly conserved amino acid residue located in a domain of the FKTN protein that is not known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Arg146Gln substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Arg146Gln change remains unknown at this time.
Ambry Genetics RCV002328768 SCV002633012 uncertain significance Cardiovascular phenotype 2021-12-23 criteria provided, single submitter clinical testing The p.R146Q variant (also known as c.437G>A), located in coding exon 4 of the FKTN gene, results from a G to A substitution at nucleotide position 437. The arginine at codon 146 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Fulgent Genetics, Fulgent Genetics RCV002502111 SCV002812314 uncertain significance Dilated cardiomyopathy 1X; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4; Autosomal recessive limb-girdle muscular dystrophy type 2M; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1; Muscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4 2021-08-03 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV000396885 SCV003832688 uncertain significance not provided 2020-09-24 criteria provided, single submitter clinical testing
Natera, Inc. RCV000687793 SCV002079570 uncertain significance Walker-Warburg congenital muscular dystrophy 2020-01-24 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.